A5073438436- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Hemophilia Treatment and Research
- Renal Transplantation Outcomes and Treatments
- Platelet Disorders and Treatments
- Rheumatoid Arthritis Research and Therapies
- Monoclonal and Polyclonal Antibodies Research
- Renal Diseases and Glomerulopathies
- Blood Coagulation and Thrombosis Mechanisms
- Complement system in diseases
- Systemic Lupus Erythematosus Research
- Venous Thromboembolism Diagnosis and Management
- COVID-19 and healthcare impacts
- Sepsis Diagnosis and Treatment
- Long-Term Effects of COVID-19
- Blood groups and transfusion
- Immunotherapy and Immune Responses
- Drug Transport and Resistance Mechanisms
- Diet and metabolism studies
- Peripheral Neuropathies and Disorders
- Blood properties and coagulation
- Animal Virus Infections Studies
- Vaccine Coverage and Hesitancy
- Systemic Sclerosis and Related Diseases
Medical University of Vienna
2016-2025
Zentrum für Labormedizin
2022
FWF Austrian Science Fund
2016
GTx (United States)
2014
Zero to Three
2011
Wilhelminen Hospital
2011
Abstract Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We conducted the prospective, open-label, single-arm, phase TUXEDO-1 trial. enrolled patients aged ≥18 years HER2-positive cancer and newly diagnosed untreated brain metastases or progressing after previous local therapy, exposure to trastuzumab pertuzumab no indication for immediate therapy. Patients received...
Export Late antibody-mediated rejection (ABMR) is a leading cause of kidney allograft failure. Uncontrolled studies have suggested efficacy the proteasome inhibitor bortezomib, but no systematic trial has been undertaken to support its use in ABMR. In this randomized, placebo-controlled (the Bortezomib Antibody-Mediated Kidney Transplant Rejection [BORTEJECT] Trial), we investigated whether two cycles bortezomib (each cycle: 1.3 mg/m2 intravenously on days 1, 4, 8, and 11) prevent GFR...
Objective— An increased mean platelet volume (MPV), as an indicator of larger, more reactive platelets resulting from turnover, may represent a risk factor for overall vascular mortality, including myocardial infarction. We intended to identify patients at higher dying disease in large, hospital-based cohort. Methods and Results— A total 206 554 first-ever admissions the Allgemeines Krankenhaus Wien determination MPV between January 1996 July 2003 were included. Primary end points mortality...
Evidence suggests that B cell-depleting therapy with rituximab (RTX) affects humoral immune response after vaccination. It remains unclear whether RTX-treated patients can develop a and T-cell-mediated against SARS-CoV-2 immunisation.Patients under RTX treatment (n=74) were vaccinated twice either mRNA-1273 or BNT162b2. Antibodies quantified using the Elecsys Anti-SARS-CoV-2 S immunoassay receptor-binding domain (RBD) of spike protein neutralisation tests. SARS-CoV-2-specific T-cell...
Reliable quantification of the antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly relevant, e.g., for identifying possible vaccine failure and estimating time protection. Therefore, we evaluated five different anti-SARS-CoV-2 assays regarding anti-spike (S) antibodies. Sera from 69 SARS-CoV-2-naive individuals 21 ± 1 days after vaccination with a single dose BNT162b2 (Pfizer/BioNTech) were tested using following quantitative assays: Roche S total...
Brain metastases (BM) are a devastating complication of HER2-positive metastatic breast cancer (BC) and treatment strategies providing optimized local systemic disease control urgently required. The antibody-drug conjugate trastuzumab deruxtecan (T-DXd) improved progression-free survival (PFS) overall (OS) over emtansine but data regarding intracranial activity is limited. In the primary outcome analysis TUXEDO-1, high response rate (RR) was reported with T-DXd. Here, we report final PFS OS results.
Abstract Background In the context of COVID-19 pandemic, numerous new serological test systems for detection anti-SARS-CoV-2 antibodies rapidly have become available. However, clinical performance many these is still insufficiently described. Therefore, we compared 3 commercial CE-marked, SARS-CoV-2 antibody assays side by side. Methods We included a total 1154 specimens from pre-COVID-19 times and 65 samples patients (≥14 days after symptom onset) to evaluate Abbott, Roche, DiaSorin....
Advanced macrolides, such as azithromycin (AZM) or clarithromycin (CLM), are antibiotics with immunomodulatory properties. Here we have sought to evaluate their in vitro influence on the activation of CD4+ T-cells. Isolated T-cells were stimulated agonistic anti-CD3/anti-CD28 monoclonal antibodies presence 0.6 mg/L, 2.5 10 mg/L 40 AZM CLM. Cell proliferation, cytokine level supernatants and cell viability was assessed. Intracellular signaling pathways evaluated using reporter lines, FACS...
Background and Aim: It is increasingly recognized that biomedical research has serious reproducibility issues, which could be overcome at least in part by standardized processing of biomaterials. Therefore, professional biobanks have emerged, positively influencing sample data quality. However, quantitative about a biobank's contribution to published results are still hard find, although they serve as valuable benchmark figures for the community. We therefore aimed report usage from MedUni...
Background. Late antibody-mediated rejection (AMR) is a major cause of transplant failure. Potential therapeutic targets are plasma cells and natural killer (NK) cells, both expressing high levels CD38. Methods. Here, we report the use CD38 monoclonal antibody daratumumab (9-mo course) in kidney allograft recipient diagnosed with smoldering myeloma anti-HLA class II donor-specific antibody-positive chronic active AMR 13 years after transplantation. Patient monitoring included serial HLA...
To our knowledge, little is known about antibody development after SARS-CoV-2 vaccination in immunocompromised individuals, such as patients with cancer.To determine whether hematooncological develop anti-SARS-CoV-2 antibodies vaccination.This retrospective cohort study included 2 independent cohorts of who were treated for hematological and solid malignant tumors between October 2020 May 2021, comprising 901 samples from 595 58 health care workers (HCWs). Serum collected at an academic...
SARS-CoV-2-induced COVID-19 has led to exponentially rising mortality, particularly in immunosuppressed patients, who inadequately respond conventional vaccination.In this blinded randomised clinical trial, we compare the efficacy and safety of an additional booster vaccination with a vector versus mRNA vaccine non-seroconverted patients. We assigned 60 patients under rituximab treatment, did not seroconvert after their primary either BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna),...
Abstract Objective Ankle‐brachial index (ABI) and carotid‐femoral pulse‐wave velocity (cfPWV) are well‐established surrogate markers of overall cardiovascular risk. However, their prognostic value towards short‐ long‐term mortality in an emergency medicine setting is yet unknown. Approach Results Acutely ill medical patients systematically underwent cfPWV ABI measurements at the department a tertiary care hospital. Patients' survival was analysed relation to values initial presentation. In...
Circulating donor-specific antibodies (DSA) detected on bead arrays may not inevitably indicate ongoing antibody-mediated rejection (AMR). Here, we investigated whether detection of complement-fixation, in parallel to IgG mean fluorescence intensity (MFI), allows for improved prediction AMR.Our study included 86 DSA+ kidney transplant recipients subjected protocol biopsy, who were identified upon cross-sectional antibody screening 741 with stable graft function at 6 months or longer after...
Anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) are the most commonly used diagnostic markers of arthritis (RA). These predominantly IgM or IgG isotype. Other subtypes both – particularly IgA isotypes- other autoantibodies such as RA33 have been repeatedly reported but their value has still not fully elucidated. Here, we investigated prevalence IgA, RF, ACPA in patients with RA. To determine specificity sensitivity sera from 290 RA (165 early 125 established disease),...
Data on clinical characteristics and the prevalence of underlying coagulopathies in patients with mild-to-moderate bleeding disorders (MBDs) are scarce.We established Vienna Bleeding Biobank (VIBB) to characterize thoroughly investigate Austrian MBDs.Four hundred eighteen (female = 345, 82.5%) were included. A platelet function defect (PFD) was diagnosed 26 (6.2%) a possible PFD 30 (7.2%) patients. Eight (1.9%) von Willebrand disease (VWD) (type 1 n 6; type 2 2), 29 had low VWF (30-50...
Drug-induced immunosuppression in kidney transplant recipients is crucial to prevent allograft rejection, but increases risk for infectious disease. Immunologic monitoring tailor immunosuppressive drugs might alloreactivity and adverse effects simultaneously. The apathogenic torque teno virus (TTV) reflects the immunocompetence of its host act as a potential candidate holistic monitoring. We screened all 1010 consecutive patients from prospective Vienna Kidney Transplant Cohort Study...
Abstract Neurofilament light chain (NfL) has emerged as a biomarker of neuroaxonal damage in several neurologic conditions. With increasing availability fourth-generation immunoassays detecting NfL blood, aspects pre-analytical stability this remain unanswered. This study investigated concentrations serum and plasma samples 32 patients with neurological diagnoses using state the art Simoa technology. We tested effect delayed freezing up to 7 days statistically determined validity measured...
Objective The study was undertaken to assess the impact of B cell depletion on humoral and cellular immune responses severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) vaccination in patients with various neuroimmunologic disorders anti‐CD20 therapy. This included an analysis T vaccine response SARS‐CoV‐2 Delta variant. Methods We investigated prospectively mRNA 82 therapy age‐ sex‐matched healthy controls. For quantification antibodies, Elecsys anti‐SARS‐CoV‐2 viral spike (S)...
Due to potentially immune-escaping virus variants and waning immunity, a third SARS-CoV-2 vaccination dose is increasingly recommended. However, data in patients with cancer are limited.We measured anti-SARS-CoV-2 spike protein antibody levels after the 439 41 health care workers (HCW) at an academic centre Austria rural community hospital Italy. Adverse events were retrieved from questionnaires.Overall, HCW included. infections observed 62/439 (14.1%) before 5/439 (1.1%) ≥1 dose....
Patients under rituximab therapy are at high risk for a severe COVID-19 disease course. Humoral immune responses to SARS-CoV-2 vaccination vastly diminished in B-cell-depleted patients, even after third vaccine dose. However, it remains unclear whether these patients benefit from fourth and continued affects antibody development.In this open-label extension trial, 37 rituximab-treated who received dose with either vector or mRNA-based were vaccinated time an (mRNA-1273 BNT162b2). Key...
The SARS-CoV-2 Omicron variant is characterized by substantial changes in the antigenic structure of Spike (S) protein. Therefore, antibodies induced primary infection lack neutralizing activity against earlier variants. In this study, we analyzed whether these impact sensitivity commercial anti-SARS-CoV-2 antibody assays. Sera from 37 unvaccinated, convalescent individuals after putative were tested with a panel 20 immunoassays. As controls, used samples 43 ancestral wild-type strain....